Isabelle Ray-Coquard, Medical Oncologist at Léon Bérard Center, shared a post on LinkedIn, about a paper by her and colleagues, published in Annals of Oncology:

“Paola-1 publications, new episode in Annals of Oncology 2024 revealing that subsequent therapies can be impacted differently after 1st line maintenance with parpi and bevacizumab or bevacizumab alone…

Very proud to share this academic international collaborative new publication from ENGOTov25 Paola-1 study.”

“Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.”

Authors: P. Harter, C. Marth, M. Mouret-Reynier, E. Pujade-Lauraine, I. Ray-Coquard et al.

Isabelle Ray-Coquard: New publication from ENGOTov25 Paola-1 study

More posts featuring Isabelle Ray-Coquard.